3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Veronica Wu of First Bight Ventures, BJ Schaknowski of symplr, and Mikyoung Jun of the University of Houston. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know — the first of this new year — I'm introducing you to three local innovators across industries — from health care innovation to energy — recently making headlines in Houston innovation.

Veronica Wu, founder of First Bight Ventures

Veronica Wu, who moved to Houston from Silicon Valley last year, has launched a new venture capital firm to help accelerate synthetic biology startups. Photo courtesy of First Bight Ventures

Veronica Wu is a relative newcomer to Houston. She made the move from Silicon Valley to the Bayou City in the middle of 2021. Wu has announced the launch of First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups, and based right here in Houston. She plans to leverage the local market to incubate these startups locally, according to the release.

“Houston is well positioned to become a major center for synthetic biology with its existing talent, industries, and capital," she says.

Wu has over 20 years of experience in managerial positions at tech companies like Apple, Tesla, and Motorola, and she served as a founding team member of McKinsey & Company’s Greater China office's business technology practice. Click here to read more.

BJ Schaknowski, CEO of symplr

Houston-based symplr has made another strategic acquisition as it grows its software offerings to its health care clients. Image via symplr.com

Symplr will acquire the Midas platform, which provides users with operations efficiency via data analytics, from New Jersey-based Conduent Incorporated (Nasdaq: CNDT). The deal, valued at $340 million, is expected to close in the first quarter of 2022.

"Midas Health Analytics Solutions brings actionable data and insights to help symplr's health system clients improve patient care and deliver better outcomes," says BJ Schaknowski, CEO of symplr, in a news release. "With integrated quality outcomes and machine learning-based advanced analytics, our combined compliance, quality and safety software portfolio can better predict patient specific risks, deliver population health insights, and proactively improve and support business intelligence performance further advancing symplr's mission of transforming healthcare operations." Click here to read more.

Mikyoung Jun, ConocoPhillips professor of data science at the UH College of Natural Science and Mathematics

A new UH-led program will work with energy corporations to prepare the sector's future workforce. Photo via UH.edu

The Data Science for Energy Transition project, which is funded through 2024 by a $1.49 million grant from the National Science Foundation, includes participation from UH, the University of Houston-Downtown, the University of Houston-Victoria, the University of Houston-Clear Lake, and Sam Houston State University.

At the helm of the initiative is principal investigator Mikyoung Jun, ConocoPhillips professor of data science at the UH College of Natural Science and Mathematics.

“It’s obvious that the Houston area is the capital for the energy field. We are supporting our local industries by presenting talented students from the five sponsoring universities and other Texas state universities with the essential skills to match the growing needs within those data science workforces,” Jun says in the release. “We’re planning all functions in a hybrid format so students located outside of Houston, too, can join in.” Click here to read more.

Houston-based symplr has made another strategic acquisition as it grows its software offerings to its health care clients. Image via symplr.com

Houston health tech company makes $340M deal to acquire analytics biz

m&a moves

A tech-enabled Houston health care operations business has announced another strategic acquisition that would close before the end of the quarter.

Houston-based symplr, which provides software solutions for governance, risk management, and compliance and is backed by California-based Clearlake Capital Group L.P. and Massachusetts-based Charlesbank Capital Partners, announced this week that it will acquire Midas Health Analytics Solutions. Symplr will acquire the Midas platform, which provides users with operations efficiency via data analytics, from New Jersey-based Conduent Incorporated (Nasdaq: CNDT). The deal, valued at $340 million, is expected to close in the first quarter of 2022.

Midas brings to the table a vast data warehouse with over 100 million claims and 30,000 indicators, according to the release, and comparative data from an estimated 800 hospitals.

"As part of our strategy to streamline our portfolio, we consider divestitures of select businesses in order to enhance shareholder and client value." says Cliff Skelton, Conduent president and CEO, in the release. "We believe this is a mutually beneficial transaction and we are focused on providing a seamless transition for our clients. We are committed to delivering robust business process solutions to all industries, including the healthcare industry."

Symplr has been on a bit of a roll when it comes to acquisitions. In March, InnovationMap reported that the SaaS company acquired Phynd Technologies, and symplr went on to acquire another handful of companies throughout 2021. Looking back, symplr has made over a dozen acquisitions and was recognized among the fastest-growing tech companies by Deloitte in 2020.

"The Midas acquisition further strengthens symplr's comprehensive healthcare operations SaaS solutions that enable hospitals and health systems to efficiently navigate the complexities of integrating critical business operations," says Behdad Eghbali, co-founder and managing partner of Clearlake, which acquired symplr in 2018. "We look forward to supporting the company as it continues driving industry consolidation and accelerating organic growth through our O.P.S. value creation framework."

Houston-based symplr has acquired a Dallas SaaS company as it grows its software offerings to its health care clients. Image via symplr.com

Houston health care SaaS company makes strategic acquisition

keep it symplr

A Houston-based health tech company is on an acquisition roll — it's latest deal marks the 11th acquisition in six years.

Software-as-a-service company symplr, which makes health care governance, risk management, and compliance software, has acquired Dallas-based data management SaaS company, Phynd Technologies. Symplr, which is backed by Clearlake Capital Group L.P. and SkyKnight Capital, did not disclose the terms of the transaction.

Symplr's burst of M&A activity spurs from the growing company's mission of providing end-to-end healthcare GRC portfolio, according to a news release. Phynd's platform manages data to provider profiles, locations, clinical expertise, availability, and health plan and network participation.

"Delivering new and significant ongoing value to our customers is integral to symplr's mission. Bringing Phynd into the symplr family helps us further deliver on that promise," says BJ Schaknowski, CEO of symplr, in the news release. "Phynd will integrate with our existing provider software solutions to create an end-to-end provider data management platform for hospitals, health systems, and payers that is unmatched in the healthcare industry today. We're excited to continue leading the healthcare GRC industry with innovative solutions that drive meaningful change."

Phynd was founded in 2012 and raised its $8 million series B in January 2019, according to Crunchbase.

"In the digital healthcare era, organizations must manage their providers and locations as searchable products that are accessible by consumers, referring providers and staff, and care delivery and revenue cycle teams. The combination of symplr and Phynd offers a unique, holistic provider data management offering that includes all providers, locations and virtual visits, helping healthcare organizations become more efficient and competitive," says Tom White, CEO of Phynd, in the release.

"symplr now offers the most robust and scalable central hub of continuously-curated credentialed and referring provider data. We are enthusiastic about executing as one organization and jointly expanding symplr's market leadership," he continues.

The Phynd acquisition is the sixth since symplr formed its partnership with private equity firms Clearlake and SkyKnight in 2018. Based in Santa Monica and Dallas, Clearlake is focused on software solutions across industries and currently has approximately $30 billion of assets under management. San Francisco-based SkyKnight Capital manages over $1.5 billion of PE capital and invests in healthcare, insurance, and business services.

Last year, symplr was named to Deloitte's 26th annual North America Technology Fast 500.The companies on the list were selected based on percentage fiscal year revenue growth from 2016 to 2019. The company came in at No. 426 on the national list with 221 percent growth.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."

7 Houston neighbors named to U.S. News' best places to live in 2026

Living Well

Several Houston suburbs have been crowned the best places to live in the U.S. for 2026, according to U.S. News & World Report. Sugar Land is the highest-ranked city in the Houston metro, and it ranks as the 10th best place to live in the country.

The annual list of Best Places to Live in the U.S. is designed to help readers make the most informed decisions when choosing where to settle down, using data from sources such as the U.S. Census Bureau, Department of Commerce, the Federal Reserve and the Bureau for Economic Analysis, as well as state and local sources.

For the 2026-2027 rankings, U.S. News featured 250 U.S. cities and ranked them across four livability indexes — quality of life, value, desirability, and job market — weighted by importance based on survey results of approximately 500 Americans. The rankings were also broken down state-by-state, as well as the best big, medium, and small cities overall.

Sugar Land is the No. 4 best places to live in Texas, and it soared into the No. 10 spot overall in the nation after ranking 16th last year. Sugar Land also ranks as the fourth-best mid-sized city to live in America for 2026-2027.

According to U.S. News, Sugar Land's median household income is far higher than the national average. Residents make $140,511 per year, while the average American household income is only $83,181.

Additionally, the $431,815 median home value in Sugar Land is also far greater than the $359,870 national average.

After ranking in the top 10 in the 2025 report, League City and Pearland now both rank outside the national top 10 for 2026. League City slipped from No. 6 to No. 13 this year, while Pearland dropped from No. 3 nationwide to No. 16.

These three Houston suburbs also boast highly desirable job markets for potential newcomers or current residents that want to start or change their career.

Houston proper, however, remains outside of the top 250 and is the 327th best place to live in the U.S., and it's the 60th best place to live in Texas.

Other cities in the greater Houston area that ranked among the top 100 include:

No. 28 – The Woodlands
No. 38 – Katy
No. 61 – Missouri City
No. 82 – Spring

The Lone Star State had a "strong showing" in the overall top 10 thanks to its "high affordability scores," a release said. Besides Sugar Land, three more popular Texas suburbs made the cut: Leander (No. 8) outside Austin and Dallas-Fort Worth suburbs Flower Mound (No. 3) and Frisco (No. 9).

"As prices of everyday goods continue to rise, consumers are considering affordability as a top priority when choosing a place to live," said U.S. News consumer lending analyst Erika Giovanetti. "While U.S. News’ consumer survey indicated that quality of life and affordability were close in importance, cost-of-living concerns resulted in many Americans putting what they can afford above their aspirations."

---

This article originally appeared on CultureMap.com.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME